A detailed history of Kathmere Capital Management, LLC transactions in Novartis Ag stock. As of the latest transaction made, Kathmere Capital Management, LLC holds 17,770 shares of NVS stock, worth $1.84 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares
17,770
Previous 13,714 29.58%
Holding current value
$1.84 Million
Previous $1.46 Million 40.03%
% of portfolio
0.2%
Previous 0.16%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$106.13 - $120.89 $430,463 - $490,329
4,056 Added 29.58%
17,770 $2.04 Million
Q2 2024

Jul 17, 2024

BUY
$92.57 - $107.37 $235,683 - $273,364
2,546 Added 22.8%
13,714 $1.46 Million
Q2 2024

Jul 01, 2024

SELL
$92.57 - $107.37 $121,359 - $140,762
-1,311 Reduced 10.51%
11,168 $1.19 Million
Q1 2024

Apr 16, 2024

BUY
$95.27 - $108.47 $124,898 - $142,204
1,311 Added 11.74%
12,479 $1.21 Million
Q4 2023

Apr 16, 2024

SELL
$92.27 - $101.54 $7,658 - $8,427
-83 Reduced 0.74%
11,168 $1.13 Million
Q3 2023

Oct 11, 2023

BUY
$94.73 - $105.13 $93,403 - $103,658
986 Added 9.61%
11,251 $1.15 Million
Q2 2023

Jul 11, 2023

BUY
$92.52 - $104.91 $69,852 - $79,207
755 Added 7.94%
10,265 $1.04 Million
Q1 2023

Apr 20, 2023

BUY
$80.03 - $92.81 $20,727 - $24,037
259 Added 2.8%
9,510 $874,000
Q4 2022

Jan 24, 2023

SELL
$75.55 - $92.52 $139,540 - $170,884
-1,847 Reduced 16.64%
9,251 $0
Q4 2022

Jan 24, 2023

BUY
$75.55 - $92.52 $838,453 - $1.03 Million
11,098 New
11,098 $0
Q2 2022

Aug 09, 2022

BUY
$80.52 - $93.75 $75,527 - $87,937
938 Added 28.91%
4,182 $354,000
Q1 2022

Apr 28, 2022

SELL
$80.11 - $90.62 $35,008 - $39,600
-437 Reduced 11.87%
3,244 $285,000
Q3 2020

Nov 13, 2020

BUY
$82.14 - $91.0 $302,357 - $334,971
3,681 New
3,681 $322,000

Others Institutions Holding NVS

About NOVARTIS AG


  • Ticker NVS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,151,000,064
  • Market Cap $223B
  • Description
  • Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...
More about NVS
Track This Portfolio

Track Kathmere Capital Management, LLC Portfolio

Follow Kathmere Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kathmere Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kathmere Capital Management, LLC with notifications on news.